SEC Comment Letter 0000000000-23-004518 to Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464) (ATRA)
Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464)
Date: May 2, 2023 · CIK: 0001604464 · Accession: 0000000000-23-004518
AI Filing Summary & Sentiment
File numbers found in text: 001-36548
Letter
United States securities and exchange commission logo May 2, 2023 Pascal Touchon President and Chief Executive Officer Atara Biotherapeutics, Inc. 2380 Conejo Spectrum Street Suite 200 Thousand Oaks, CA 91320 Re:Atara Biotherapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Filed February 8, 2023 File No. 001-36548 Dear Pascal Touchon: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 2, 2023
Pascal Touchon
President and Chief Executive Officer
Atara Biotherapeutics, Inc.
2380 Conejo Spectrum Street
Suite 200
Thousand Oaks, CA 91320
Re:Atara Biotherapeutics, Inc.
Form 10-K for Fiscal Year Ended December 31, 2022
Filed February 8, 2023
File No. 001-36548
Dear Pascal Touchon:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences